Transferring knowledge and continuing to work together with regulatory agencies will lead to changes in approval going forward.
Regulatory agencies are open to changes within the review process which means the uptake of CAR T-cell therapy will change the landscape itself. This is especially true with large-scale commercialization. Information sharing between global agencies will also be helpful in advancing the science forward.
An Evolving ‘Opinion’ Landscape: New Paths—and Synergies—for Pharma KOLs & DOLs
October 13th 2023Industry experts discuss the relationship between digital and traditional (key) opinion leaders and how companies are adjusting their strategies to harness the unique brand engagement benefits each role can provide in driving better patient outcomes.